Sale!

JAK2 Gene Leukemia Acute Myelogenous Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The JAK2 Gene Leukemia Acute Myelogenous Genetic Test is a specialized diagnostic tool used to detect mutations in the JAK2 gene, which are commonly associated with various types of blood cancers, including acute myelogenous leukemia (AML). This test plays a crucial role in the diagnosis and management of AML, helping healthcare professionals to tailor treatment plans based on the genetic makeup of the leukemia. The presence of JAK2 mutations can influence the prognosis and response to certain therapies, making this test an essential part of the diagnostic process.

Conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities, the test offers precise and reliable results. The cost of the JAK2 Gene Leukemia Acute Myelogenous Genetic Test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify the JAK2 gene mutations. By opting for this test, patients and healthcare providers can gain valuable insights into the genetic factors of AML, facilitating more effective and personalized treatment strategies.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

JAK2 Gene Leukemia Acute Myelogenous Genetic Test

At DNA Labs UAE, we offer the JAK2 Gene Leukemia Acute Myelogenous Genetic Test to provide valuable insights into the genetic basis of acute myelogenous leukemia (AML) and guide personalized treatment approaches.

Test Details

The JAK2 gene is a protein-coding gene that plays a crucial role in regulating the production and function of blood cells. Mutations in the JAK2 gene are commonly associated with a group of blood disorders known as myeloproliferative neoplasms (MPNs), including AML.

Our Next-Generation Sequencing (NGS) technology allows us to analyze the DNA sequence of the JAK2 gene, identifying any mutations or variations that may be present. This information can provide important insights into the genetic basis of AML and help guide treatment decisions.

NGS genetic testing for JAK2 gene mutations in AML can be performed on a blood or bone marrow sample. The test involves extracting DNA from the sample and sequencing the JAK2 gene to identify any mutations, such as the JAK2 V617F mutation commonly found in MPNs. These mutations lead to the overactivation of the JAK2 protein, causing abnormal cell growth and proliferation.

Test Components and Price

Test Name: JAK2 Gene Leukemia Acute Myelogenous Genetic Test

Components: NGS Technology

Price: 4400.0 AED

Sample Condition and Report Delivery

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Test Type and Doctor

Test Type: Cancer

Doctor: Oncologist

Test Department and Pre Test Information

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for JAK2 Gene Leukemia Acute Myelogenous NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with JAK2 Gene Leukemia Acute Myelogenous NGS Genetic DNA Test gene JAK2.

Conclusion

NGS genetic testing for JAK2 gene mutations in AML can provide valuable information about the genetic basis of the disease and help tailor treatment approaches to individual patients. It is important to note that genetic testing for JAK2 mutations is not typically performed as a standalone diagnostic test for AML. It is usually conducted in conjunction with other diagnostic tests, such as blood tests, bone marrow biopsy, and cytogenetic analysis, to provide a comprehensive assessment of the disease.

Test Name JAK2 Gene Leukemia acute myelogenous Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Cancer
Doctor Oncologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for JAK2 Gene Leukemia, acute myelogenous NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with JAK2 Gene Leukemia, acute myelogenous NGS Genetic DNA Test gene JAK2
Test Details

The JAK2 gene is a protein-coding gene that plays a crucial role in regulating the production and function of blood cells. Mutations in the JAK2 gene are commonly associated with a group of blood disorders known as myeloproliferative neoplasms (MPNs), including a type of leukemia called acute myelogenous leukemia (AML).

Next-generation sequencing (NGS) genetic testing is a powerful tool used to analyze the DNA sequence of genes, including the JAK2 gene, to identify any mutations or variations that may be present. This type of testing can provide important information about the genetic basis of diseases, such as AML, and help guide treatment decisions.

In the case of JAK2 gene mutations, NGS genetic testing can detect specific mutations, such as the JAK2 V617F mutation, which is commonly found in MPNs. This mutation leads to the overactivation of the JAK2 protein, causing abnormal cell growth and proliferation.

NGS genetic testing for JAK2 gene mutations in AML can be performed on a blood or bone marrow sample. The test involves extracting DNA from the sample and sequencing the JAK2 gene to identify any mutations. The results of the test can help confirm the diagnosis of JAK2-related AML and guide treatment decisions.

It is important to note that genetic testing for JAK2 mutations is not typically performed as a standalone diagnostic test for AML. It is usually conducted in conjunction with other diagnostic tests, such as blood tests, bone marrow biopsy, and cytogenetic analysis, to provide a comprehensive assessment of the disease.

Overall, NGS genetic testing for JAK2 gene mutations in AML can provide valuable information about the genetic basis of the disease and help tailor treatment approaches to individual patients.